Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors-Reference-Cited by-同舟云学术

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Published:2011-03-23 Issue:75 Volume:3 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sequist Lecia V.¹²,Waltman Belinda A.²,Dias-Santagata Dora²³,Digumarthy Subba²⁴,Turke Alexa B.¹²,Fidias Panos¹²,Bergethon Kristin³,Shaw Alice T.¹²,Gettinger Scott⁵,Cosper Arjola K.¹,Akhavanfard Sara²³,Heist Rebecca S.¹²,Temel Jennifer¹²,Christensen James G.⁶,Wain John C.¹²⁷,Lynch Thomas J.⁵,Vernovsky Kathy¹,Mark Eugene J.²³,Lanuti Michael¹²⁷,Iafrate A. John²³,Mino-Kenudson Mari²³,Engelman Jeffrey A.¹²

Affiliation:

1. Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

2. Harvard Medical School, Boston, MA 02115, USA.

3. Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.

4. Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.

5. Yale University School of Medicine and Yale Cancer Center, New Haven, CT 06520, USA.

6. Translational Pharmacology, Pfizer Oncology, La Jolla, CA 92121, USA.

7. Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.

Abstract

Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference64 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

4. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

5. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Cited by 2862 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and evaluation of a rociletinib analog as prospective imaging double mutation L858R/T790M in non-small cell lung cancer;Journal of Pharmacy & Pharmacognosy Research;2024-03-01

2. Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway;Pharmacological Research;2024-03

3. Small cell lung cancer transformations from non-small cell lung cancer: Biological mechanism and clinical relevance;Chinese Medical Journal Pulmonary and Critical Care Medicine;2024-02

4. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review;Critical Reviews in Oncology/Hematology;2024-02

5. Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents;Medicinal Research Reviews;2024-01-27